Allarity Spins Off SPAC: $100M IPO for Allarity Acquisition Corp.
ALLR sits 57% above its 52-week low of $0.769.
Summary
Allarity Therapeutics announced that its wholly-owned subsidiary is sponsoring a new SPAC, Allarity Acquisition Corp., which has filed for a $100 million IPO on Nasdaq under ticker ALLNU.
Key Events · Financing and Capital Events · ALLR
-
SPAC IPO Filed
Allarity Acquisition Corp., a newly formed SPAC sponsored by Allarity's wholly-owned subsidiary ALLR Sponsor LLC, has publicly filed a Form S-1 for a proposed IPO of units.
-
Offering Size
Base offering size of $100 million, or $115 million if underwriters exercise their over-allotment option in full.
-
Sponsor Ownership
ALLR Sponsor LLC is expected to own approximately 25.0% of Allarity Acquisition Corp.'s issued and outstanding ordinary shares following completion of the offering.
-
Leadership
Jesper Hoiland, a current Allarity board member and former EVP and President of Novo Nordisk, will serve as Chairman of the SPAC's board.
Analysis · ALLR · Life Sciences
Allarity Therapeutics is launching a SPAC through its wholly-owned subsidiary, ALLR Sponsor LLC, which has filed for a $100 million IPO (up to $115 million with over-allotment). The sponsor will retain roughly 25% ownership of the SPAC after the offering. This is a strategic capital allocation move that could provide Allarity with a new vehicle for future acquisitions while potentially generating sponsor economics, but it also diverts management attention and carries SPAC-related risks. The offering does not change Allarity's previously disclosed expectation of sufficient working capital into summer 2028.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALLR was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.3M. The 52-week trading range was $0.77 to $1.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.